PPARG and liver cancer: Consistent with previous findings, we found that PPARG activation in liver cancer cells by E2 and ER agonists inhibits proliferation, induces cell cycle arrest (Figures 1(a) and 3(b)) [78, 83–85], and induces apoptosis through caspase 3 activation (Figure 1(c)) [78, 86].